Increase in Prevalence of Cancer Expected to Drive Europe Cancer Screening Market over the Forecast Period: Ken Research REQUEST FOR SAMPLE REPORT Buy Now Request For sample Report × Report Title Name Email Designation Phone No Comapny Name Comapny URL Country -- Please Select Your Country -- Afganistan Africa Albania Algeria Andorra Angola Anguilla Antigua and Barbuda Argentina Armenia Aruba Asia Australasia Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bonaire Bosnia Herzegovina Botswana Brazil BRICS British Virgin Islands Brunei Darussalam Bulgaria Burkina Faso Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Central and South America Chad Chile China Colombia Comoros Congo Costa Rica Cote d'Ivoire Croatia Cuba Curacao Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Europe European Union Falkland Islands Faroe Islands Fiji Finland France French Guiana French Polynesia Gabon Gambia Georgia Germany Ghana Gibraltar Global Great Britain Greece Greenland Grenada Guadeloupe Guam Guatemala Guerney & Alderney Guinea Guinea-Bissau Guyana Haiti Honduras Hong Kong Hungary Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Ivory Coast Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kosovo Kuwait Kyrgyzstan Laos Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Macau Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Man (Island of) Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Micronesia Middle East Minnesota Moldova Monaco Mongolia Monserrat Montenegro Morocco Morroco Mozambique Myanmar Namibia Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria Niue North America North Korea Norway Oman Pakistan Palau Palestine Panama Papua New Guinea Paraguay Peru Philippines Poland Portugal Puerto Rico Qatar Reunion Romania Russia Rwanda Saint Helena Saint Lucia Saint Martin Saint Pierre and Miquelon Saint Vincent and the Grenadines Samoa Samoa (American) San Marino Sao Tome and Principe Saudi Arabia Scandinavia Senegal Serbia Seychelles Sierra Leone Singapore Sint Maarten Slovakia Slovenia Solomon (Islands) Somalia South Africa South Korea South Sudan Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Islands Swaziland Sweden Switzerland Syria Taiwan Tajikistan Tanzania Thailand Timor Leste Togo Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Uganda Ukraine United Arab Emirates United Kingdom United States Uruguay Uzbekistan Vanuatu Vatican City Venezuela Vietnam Virgin Islands Western Sahara Yemen Zambia Zimbabwe Requirement Submit Certain tests help find precise types of cancer before signs or symptoms appear, called cancer screening. It main goal is to reduce the number of people who develop the disease and reduce the number of people who die from disease & prevent deaths from cancer altogether. It involves urine tests, blood tests and medical imaging tests. Some of the risk associated with cancer screening are increased testing, false positives test results, over diagnosis & over treatment and false reassurance. According to study, “Europe Cancer Screening Market (2018-2023)” the key companies operating in the Europe cancer screening market are F. Hoffman-La- Roche Ltd, Johnson & Johnson, Bayer AG, Pfizer Inc., Merck & co., Abbott Laboratories Inc., Becton, Dickinson and Company, Agilent Technologies, GE Healthcare, C. R. Bard, Inc., Koninklijhe Philips N.V., Hologic Inc., Siemens Healthcare GmbH, Illumina, Inc., Thermo Fisher Scientific Inc., Qiagen. Healthcare professionals are focusing on expansion of effective screening solutions to check prevalence level. Early detection rises the success rate of treatment regimens. As a result, healthcare agencies & market players are promoting routine checkups through various awareness programs. Based on screening procedure, cancer screening market is segmented into laboratory, imaging, biopsy, genetic, and endoscopy tests. All screening procedures includes some tests such as breast self-examination test, clinical breast examination test, Magnetic resonance imaging (MRI), mammography and others. Mammography is a most common & popular screening test employed for breast tumor screening. Based on genders, market is segmented into men and women. Based on application, market is segmented into lung, melanoma, kidney, breast, and colorectal cancer. Kidney segment is projected to witness lucrative growth owing to rise in consumption of tobacco & alcohol during the forecast period. In addition, based on end-use, market is segmented into laboratories, hospitals, and independent physicians & clinics. The cancer screening market is driven by increase in prevalence of cancer, followed by rise in adoption of a sedentary lifestyle, increase in aging population, growth in focus of key players in the emerging economies, rise in government investments for research & development (R&D), improvement in healthcare infrastructure, and healthcare, huge patient population, growth in technological advancements & product innovations and change in environmental conditions. However, lack of associated funding & transparency in medical procedures and stringent regulations along with regulatory inter & intra state barriers may impact the market. Moreover, rise in artificial intelligence and forthcoming health revolution are key opportunities for market. Based on geography, cancer screening market is categorized as France, United Kingdom (UK) and Germany. It is estimates that the market will be reached at rapid pace owing to increase in awareness about cancer and rise in government initiatives for funding in the region. Various organizations are undertaking many initiatives to spread awareness regarding benefits of early detection, breast cancer, and available treatment options. It is expected that future of the market will be bright due to rise in availability of funds for research over the forecast period. The market is anticipated to grow at a CAGR of approximately 8.1% resulting in an annual revenue of US $22.43 billion during the forecast period (2018-2023). For more information, click on the link below: Europe Cancer Screening Market Contact Us: Ken Research Ankur Gupta, Head Marketing & Communications sales@kenresearch.com +91 9015378249 Tags: Bayer AG Cancer Screening Market Share, Breast Cancer Screening Market, Cancer Screening Blood Tests, Cancer Screening Center, Cancer Screening Europe, Cancer Screening Hospitals, Cancer Screening Market in Europe, Cancer Screening Market Research Report, Cancer Screening Test, Europe Cancer Diagnostic Market Forecasts, Europe Cancer Screening Devices Market, Europe Cancer Screening Industry Analysis, Europe Cancer Screening Industry Research Report, Europe Cancer Screening Market, Europe Cancer Screening Market Competitive landscape, Europe Cancer Screening Market Outlook, Europe Cancer Screening Market Overview, Europe Cancer Screening Market Research Report, Europe Cancer Screening Market Revenue, Europe Cancer Screening Market Segmentation, Europe Cancer Screening Market Share, Europe Cancer Screening Market Trends, Europe Cervical Cancer Diagnostics and Therapeutics Market, Europe Colorectal Cancer Screening Tests Market, F. Hoffman La Roche Ltd Cancer Screening Market Size, Germany Cancer Screening Market, Global Cancer Screening Market, Japan Cancer Screening Market, Johnson & Johnson Cancer Screening Market Revenue, Pfizer Cancer Screening Market Share, UK Cancer Screening Market Application